M4205   Click here for help

GtoPdb Ligand ID: 11510

Synonyms: compound 32 [PMID: 36728508] | IDRX-42 [1] | IDRX42 | M-4205
PDB Ligand
Compound class: Synthetic organic
Comment: M4205 is a potent and selective inhibitor of the KIT proto-oncogene, receptor tyrosine kinase (cKIT). It retains activity against cKIT with exon 11, 13 or 17 resistance mutations, and provides good selectivity in biochemical and cellular assays. M4205's ADME profile supports its potential as an orally bioavailable clinical candidate [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 10
Topological polar surface area 85.4
Molecular weight 508.27
XLogP 4.58
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Cn1ncc(c1)c1ccc(cc1)CNc1ncnc(c1)c1cnc2n1ccc(c2)OCCCN1CCCC1
Isomeric SMILES Cn1ncc(c1)c1ccc(cc1)CNc1ncnc(c1)c1cnc2n1ccc(c2)OCCCN1CCCC1
InChI InChI=1S/C29H32N8O/c1-35-20-24(18-34-35)23-7-5-22(6-8-23)17-30-28-16-26(32-21-33-28)27-19-31-29-15-25(9-13-37(27)29)38-14-4-12-36-10-2-3-11-36/h5-9,13,15-16,18-21H,2-4,10-12,14,17H2,1H3,(H,30,32,33)
No information available.
Summary of Clinical Use Click here for help
M4205, with the new research code IDRX-42 has been advanced to a first-in-human clinical study. The drug's developers have proposed IDRX-42 as a potential therapy for gastrointestinal stromal tumours.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05489237 A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors Phase 1 Interventional IDRx, Inc. This KIT inhibitor has been entered into clinical evaluation with the research code IDRX-42,